Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Eblasakimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : ASLAN Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
ASLAN and Zenyaku Expand Collaboration on Eblasakimab Mechanism
Details : The collaboration aims to support the ASLAN to further investigate their clinical development of ASLAN004 (eblasakimab), which is being evaluated in the mid-stage clinical trial for atopic dermatitis.
Brand Name : ASLAN004
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 02, 2024
Lead Product(s) : Eblasakimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : ASLAN Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Rituximab
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Chugai Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Rituxan (rituximab) is an anti-CD20 monoclonal antibody that specifically binds to CD20, a protein expressed on B cells, excluding hematopoietic stem cells and plasma cells, which is used for the treatment of Lupus Nephritis.
Brand Name : Rituxan
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 23, 2023
Lead Product(s) : Rituximab
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Chugai Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Eblasakimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : ASLAN Pharmaceuticals
Deal Size : $138.5 million
Deal Type : Licensing Agreement
Details : Under the agreement, Zenyaku gains exclusive rights to develop and commercialize ASLAN004 (eblasakimab), a potential first-in-class monoclonal antibody targeting the IL‑13 receptor subunit, in atopic dermatitis (AD) and all other indications in Japan.
Brand Name : ASLAN004
Molecule Type : Large molecule
Upfront Cash : $12.0 million
June 22, 2023
Lead Product(s) : Eblasakimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : ASLAN Pharmaceuticals
Deal Size : $138.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Rituximab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved
Sponsor : Chugai Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Rituxan (rituximab) is an anti-CD20 monoclonal antibody that specifically binds to CD20, a protein expressed on B cells, excluding stem cells and plasma cells. It attacks target B cells using the immune system equipped with the human body, and damages ce...
Brand Name : Rituxan
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 20, 2022
Lead Product(s) : Rituximab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Sponsor : Chugai Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rituximab
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Chugai Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Rituxan, an anti-CD20 monoclonal antibody got approval in additional indications of refractory pemphigus vulgaris and pemphigus foliaceus by MHLW based on results of investigator-initiated phase II clinical trial in Japan of KCTR-D006 study and PEMPHIX s...
Brand Name : Rituxan
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 24, 2021
Lead Product(s) : Rituximab
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Chugai Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?